There is a little known company that is changing warfare

With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.

Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t

Robert Spurr Biography and Net Worth

Insider of Bausch Health Companies

Bob Spurr is President, U.S. Businesses for Bausch Health, with responsibility for leading the company’s gastrointestinal, dermatology, dental, neurology and generics businesses. Bob was appointed President, Salix Pharmaceuticals in 2020 after serving as Senior Vice President, Market Access and Commercial Operations since joining the company in2018. He joined Bausch Health from Novartis’ U.S. Oncology business, where he served as Vice President, Patient Solutions and Access. He began his career at Sandoz, serving in several sales and managed markets roles over a 10-year span, before moving to Aventis. He later joined Ortho-McNeil as Vice President of Sales and Marketing for its institutional franchise. He also held sales and marketing executive leadership positions at Lantheus Medical Imaging and Repligen Corporation.

What is Robert Spurr's net worth?: The estimated net worth of Robert Spurr is at least $767,490.88 as of April 14th, 2022. Mr. Spurr owns 90,506 shares of Bausch Health Companies stock worth more than $767,491 as of November 17th. This net worth evaluation does not reflect any other investments that Mr. Spurr may own. Learn More about Robert Spurr's net worth.
How do I contact Robert Spurr?: The corporate mailing address for Mr. Spurr and other Bausch Health Companies executives is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. Bausch Health Companies can also be reached via phone at (514) 744-6792 and via email at [email protected]. Learn More on Robert Spurr's contact information.
Has Robert Spurr been buying or selling shares of Bausch Health Companies?: Robert Spurr has not been actively trading shares of Bausch Health Companies during the last quarter. Most recently, Robert Spurr sold 1,595 shares of the business's stock in a transaction on Thursday, April 14th. The shares were sold at an average price of $22.19, for a transaction totalling $35,393.05. Following the completion of the sale, the insider now directly owns 90,506 shares of the company's stock, valued at $2,008,328.14. Learn More on Robert Spurr's trading history.
Who are Bausch Health Companies' active insiders?: Bausch Health Companies' insider roster includes Christina Ackermann (EVP), Seana Carson (EVP), Richard DeSchutter (Director), Sam Eldessouky (CFO), Joseph Gordon (Insider), William Humphries (Insider), Steven Miller (Director), Robert Spurr (Insider), and Amy Wechsler (Director). Learn More on Bausch Health Companies' active insiders.
Are insiders buying or selling shares of Bausch Health Companies?: In the last year, insiders at the sold shares 2 times. They sold a total of 13,590 shares worth more than $84,651.30. The most recent insider tranaction occured on September, 6th when EVP Seana Carson sold 13,370 shares worth more than $83,027.70. Insiders at Bausch Health Companies own 8.1% of the company. Learn More about insider trades at Bausch Health Companies.
Information on this page was last updated on 9/6/2024.

Robert Spurr Insider Trading History at Bausch Health Companies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/14/2022	Sell	1,595	$22.19	$35,393.05	90,506
3/15/2022	Sell	4,846	$22.20	$107,581.20
1/18/2022	Sell	3,251	$26.63	$86,574.13

Robert Spurr Buying and Selling Activity at Bausch Health Companies

Bausch Health Companies Company Overview

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Today's Range

Now: $8.48

$8.47

$8.73

50 Day Range

MA: $8.18

$6.19

$9.78

2 Week Range

Now: $8.48

$3.96

$11.46

Volume

1,027,632 shs

Average Volume

2,020,304 shs

Market Capitalization

$3.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74